Clin2
NCT06084481Possibly a fitRecruiting

Study of a new drug for advanced solid tumors

Hepatocellular CarcinomaPancreatic Ductal AdenocarcinomaBiliary Tract CancersEsophageal Squamous Cell CarcinomaTriple Negative Breast CancerHormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast CancerHead and Neck Squamous-Cell CarcinomaPlatinum Resistant High Grade Epithelial Ovarian Cancer

Treatments studied

Part of Cancer, Digestive system, Skin clinical trials.

This study tests a new intravenous drug called ABBV-400 in people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if it can slow or stop tumor growth and to check for side effects.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
325 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have one of these cancers: liver, pancreatic, bile duct, esophageal, breast, head and neck, or ovarian cancer that has spread or cannot be removed by surgery.
  • Your cancer must be measurable on scans (like CT or MRI).
  • You must have had prior cancer treatment (chemotherapy, radiation, immunotherapy, etc.) and stopped it at least 28 days before starting the study drug.
  • You have no current or past lung problems like interstitial lung disease or pneumonitis that needed steroids.
  • You have not had untreated brain metastases, or if you have had brain metastases, they are stable and you do not need steroids for brain swelling.
  • You do not have another active cancer except for certain non-melanoma skin cancers or other early-stage cancers.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07227012Recruiting· Phase 1/Phase 2
Study of a new drug for advanced liver cancer

This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.

Irvine, California
NCT04999761Recruiting· Phase 1
Study testing new drug combinations for advanced cancers

This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.

Aichi
NCT07106827Recruiting· Phase 1
Study of a new drug for advanced or resistant solid tumors

This trial tests a new drug, GV20-0251, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and helpful.

Chengdu, Sichuan
NCT06858813Recruiting· Phase 1
ABBV-324 for advanced liver or lung cancer

This study tests an experimental IV drug (ABBV-324) for adults with advanced liver cancer (HCC) or advanced squamous lung cancer (LUSC). It aims to see if the drug is safe and whether it can help control the disease.

Duarte, California
NCT07241039Recruiting· Phase 1
Study of an oral drug for advanced squamous cell cancers

This study tests an oral drug called ABBV-711, alone or with another drug, for adults with advanced squamous cell cancers of the head, neck, or lung that have stopped responding to standard treatments. It aims to see how safe and effective the drug is.

Duarte, California
NCT06233942Recruiting· Phase 1
Testing a new drug for advanced solid tumors

This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.

Los Angeles, California

Hear when a new Hepatocellular Carcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.